Can Gossamer Bio, Inc. (GOSS)’s Tomorrow Be Different? The Stock Increases Again

The stock of Gossamer Bio, Inc. (NASDAQ:GOSS) is a huge mover today! The stock increased 5.56% or $1.08 during the last trading session, reaching $20.51. About 243,559 shares traded or 18.38% up from the average. Gossamer Bio, Inc. (NASDAQ:GOSS) has 0.00% since August 13, 2018 and is . It has by 0.00% the S&P500.
The move comes after 6 months positive chart setup for the $1.35 billion company. It was reported on Aug, 13 by Barchart.com. We have $21.54 PT which if reached, will make NASDAQ:GOSS worth $67.60 million more.

More notable recent Gossamer Bio, Inc. (NASDAQ:GOSS) news were published by: Finance.Yahoo.com which released: “Gossamer Bio, Inc. (GOSS) Q2 2019 Earnings Call Transcript – Yahoo Finance” on August 10, 2019, also Nasdaq.com with their article: “How Netflix Wants to Take on Its Competition in 2019 and Beyond – Nasdaq” published on March 21, 2019, Nasdaq.com published: “Gossamer Bio sets terms for $230 million IPO, bypassing shutdown with rarely-used 20-day rule – Nasdaq” on January 23, 2019. More interesting news about Gossamer Bio, Inc. (NASDAQ:GOSS) were released by: Benzinga.com and their article: “The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote – Benzinga” published on February 26, 2019 as well as Nasdaq.com‘s news article titled: “Tis the season for big biotechs: Gossamer Bio files for a $265 million IPO – Nasdaq” with publication date: December 21, 2018.

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company has market cap of $1.35 billion. It is developing GB001, an oral antagonist that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications. It currently has negative earnings. The firm was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.